
Helen L Pilmore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7693386/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interactions Between Donor Age and 12-Month Estimated Glomerular Filtration Rate on Allograft and Patient Outcomes After Kidney Transplantation. Transplant International, 2022, 36, 10199.	1.6	3
2	Socioâ€economic disparity, access to care and patientâ€relevant outcomes after kidney allograft failure. Transplant International, 2021, 34, 2329-2340.	1.6	2
3	Early Graft Loss Following Transplantation From Expanded Criteria Donors. Transplantation Direct, 2021, 7, e783.	1.6	2
4	Australia and New Zealand Islet and Pancreas Transplant Registry Annual Report 2019—Pancreas Waiting List, Recipients, and Donors. Transplantation Direct, 2020, 6, e564.	1.6	3
5	Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant. Journal of the American Society of Nephrology: JASN, 2020, 31, 2887-2899.	6.1	92
6	Impact of chronic kidney disease on mortality and cardiovascular outcomes after acute coronary syndrome: A nationwide data linkage study (ANZACSâ€QI 44). Nephrology, 2020, 25, 535-543.	1.6	11
7	Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation, 2020, 104, 708-714.	1.0	73
8	KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation, 2020, 104, S11-S103.	1.0	306
9	Increased Peripheral Blood Heteroplasmy of the mt.3243A>G Mutation Is Associated with Earlier End-Stage Kidney Disease: A Case Report and Review of the Literature. Nephron, 2020, 144, 358-362.	1.8	0
10	Association of prevalent vascular disease with allograft failure and mortality in liveâ€donor kidney transplant recipients – a retrospective cohort study. Transplant International, 2019, 32, 1161-1172.	1.6	0
11	Canadian-Australasian Randomised trial of screening kidney transplant candidates for coronary artery disease—A trial protocol for the CARSK study. American Heart Journal, 2019, 214, 175-183.	2.7	43
12	Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation. BMC Nephrology, 2019, 20, 147.	1.8	23
13	Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Registry-based 10-year Follow-up of 5 Randomized Trials. Transplantation, 2019, 103, 1705-1713.	1.0	4
14	Australia and New Zealand Islets and Pancreas Transplant Registry Annual Report 2018—Pancreas Waiting List, Recipients, and Donors. Transplantation Direct, 2018, 4, e390.	1.6	4
15	De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study. American Journal of Transplantation, 2018, 18, 2977-2986.	4.7	15
16	Long-term outcomes of kidney transplant recipients with end-stage kidney disease attributed to presumed/advanced glomerulonephritis or unknown cause. Scientific Reports, 2018, 8, 9021.	3.3	10
17	The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. Kidney International, 2017, 91, 954-963.	5.2	44
18	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. The Cochrane Library, 2017, 2, CD009966.	2.8	20

Helen L Pilmore

#	Article	lF	CITATIONS
19	Long-term outcomes of kidney transplantation in people with type 2 diabetes: a population cohort study. Lancet Diabetes and Endocrinology,the, 2017, 5, 26-33.	11.4	57
20	Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study. BMJ Open, 2017, 7, e016813.	1.9	14
21	Cytomegalovirus and cancer after kidney transplantation: Role of the human leukocyte antigen system?. Transplant Infectious Disease, 2017, 19, e12631.	1.7	5
22	Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial. Kidney and Blood Pressure Research, 2017, 42, 1033-1044.	2.0	7
23	Communicating projected survival with treatments for chronic kidney disease: patient comprehension and perspectives on visual aids. BMC Medical Informatics and Decision Making, 2017, 17, 137.	3.0	5
24	Deceased donor kidney transplantation in New Zealand: use and audit of a survival prediction tool. New Zealand Medical Journal, 2017, 130, 33-39.	0.5	3
25	Management of coronary artery disease in patients on dialysis. New Zealand Medical Journal, 2017, 130, 11-22.	0.5	11
26	Donor Characteristics of Pancreas Transplantation in Australia and New Zealand: A Cohort Study 1984-2014. Transplantation Direct, 2016, 2, e99.	1.6	4
27	Cardiac Screening for Kidney Transplantation. Transplantation, 2016, 100, 1396-1397.	1.0	2
28	Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 318-326.	11.4	93
29	Changes in high sensitivity troponin T in incident haemodialysis patients. New Zealand Medical Journal, 2016, 129, 23-34.	0.5	31
30	Longâ€ŧerm outcomes for primary glomerulonephritis: <scp>N</scp> ew <scp>Z</scp> ealand <scp>G</scp> lomerulonephritis <scp>S</scp> tudy. Nephrology, 2015, 20, 899-907.	1.6	31
31	A randomized, controlled trial of everolimusâ€based dual immunosuppression versus standard of care in <i>de novo</i> kidney transplant recipients. Transplant International, 2014, 27, 302-311.	1.6	39
32	Cardiovascular disease in patients with chronic kidney disease. Nephrology, 2014, 19, 3-10.	1.6	12
33	Prognostic value and long-term variation of high sensitivity troponin T in clinically stable haemodialysis patients. New Zealand Medical Journal, 2014, 127, 97-109.	0.5	3
34	Variation in and prognostic importance of troponin T measured using a high-sensitivity assay in clinically stable haemodialysis patients. CKJ: Clinical Kidney Journal, 2013, 6, 402-409.	2.9	20
35	<scp>KHAâ€CARI G</scp> uideline: <scp>R</scp> ecipient <scp>A</scp> ssessment for <scp>T</scp> ransplantation. Nephrology, 2013, 18, 455-462.	1.6	63
36	Hepatitis B–Positive Donors in Renal Transplantation. Transplantation, 2012, 94, 205-210.	1.0	39

HELEN L PILMORE

#	Article	IF	CITATIONS
37	Cardiovascular Disease Medications After Renal Transplantation: Results From the Patient Outcomes in Renal Transplantation Study. Transplantation, 2011, 91, 542-551.	1.0	45
38	KHA ARI guideline: Cytomegalovirus disease and kidney transplantation. Nephrology, 2011, 16, 683-687.	1.6	4
39	Reduction in Cardiovascular Death After Kidney Transplantation. Transplantation, 2010, 89, 851-857.	1.0	181
40	Review: Metformin: Potential benefits and use in chronic kidney disease. Nephrology, 2010, 15, 412-418.	1.6	62
41	Review article: Coronary artery stenoses: Detection and revascularization in renal disease. Nephrology, 2009, 14, 537-543.	1.6	1
42	Fatal Human Herpesvirus-6 Infection After Renal Transplantation. Transplantation, 2009, 88, 762-765.	1.0	24
43	Choice of calcineurin inhibitors in adult renal transplantation: effects on transplant outcomes. Nephrology, 2007, 12, S88-S97.	1.6	1
44	Re: "Cardiac Assessment for Renal Transplant". American Journal of Transplantation, 2006, 6, 1979-1979.	4.7	0
45	Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clinical Transplantation, 2002, 16, 191-195.	1.6	30
46	End-stage renal failure in New Zealand Maori: An analysis of circulating transforming growth factor-beta1. Nephrology, 2002, 7, 18-22.	1.6	2
47	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. The Cochrane Library, 0, , .	2.8	5